- Home
- EQS vs ADIL Comparison
EQS vs ADIL Comparison
Compare EQS & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQS | ADIL |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 18.5M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EQS | ADIL |
|---|---|---|
| Price | $1.01 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 6.8K | ★ 43.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $0.13 |
| 52 Week High | $2.36 | $7.20 |
Technical Indicators
Market Signals| Indicator | EQS | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 38.86 |
| Support Level | $0.94 | $3.84 |
| Resistance Level | $1.88 | $5.08 |
| Average True Range (ATR) | 0.03 | 0.49 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 63.34 | 11.43 |
Price Performance
Historical ComparisonAbout EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. The company invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.